PMID- 37933112 OWN - NLM STAT- MEDLINE DCOM- 20240415 LR - 20240615 IS - 2005-9256 (Electronic) IS - 1598-2998 (Print) IS - 1598-2998 (Linking) VI - 56 IP - 2 DP - 2024 Apr TI - Impact of Patient Sex on Adverse Events and Unscheduled Utilization of Medical Services in Cancer Patients Undergoing Adjuvant Chemotherapy: A Multicenter Retrospective Cohort Study. PG - 404-413 LID - 10.4143/crt.2023.784 [doi] AB - PURPOSE: The female sex is reported to have a higher risk of adverse events (AEs) from cytotoxic chemotherapy. Few studies examined the sex differences in AEs and their impact on the use of medical services during adjuvant chemotherapy. This sub-study aimed to compare the incidence of any grade and grade >/= 3 AEs, healthcare utilization, chemotherapy completion rate, and dose intensity according to sex. MATERIALS AND METHODS: This is a sub-study of a multicenter cohort conducted in Korea that evaluated the impact of healthcare reimbursement on AE evaluation in patients who received adjuvant chemotherapy between September 2013 and December 2016 at four hospitals in Korea. RESULTS: A total of 1,170 patients with colorectal, gastric, or non-small cell lung cancer were included in the study. Female patients were younger, had fewer comorbidities, and experienced less postoperative weight loss of > 10%. Females had significantly higher rates of any grade AEs including nausea, abdominal pain, stomatitis, vomiting, and neutropenia, and experienced more grade >/= 3 neutropenia, nausea, and vomiting. The dose intensity of chemotherapy was significantly lower in females, and they also experienced more frequent dose reduction after the first cycle. Moreover, female patients receiving platinum-containing regimens had significantly higher rates of unscheduled outpatient visits. CONCLUSION: Our study found that females experienced a higher incidence of multiple any-grade AEs and severe neutropenia, nausea, and vomiting, across various cancer types, leading to more frequent dose reductions. Physicians should be aware of sex differences in AEs for chemotherapy decisions. FAU - Choi, Songji AU - Choi S AD - Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea. FAU - Seo, Seyoung AU - Seo S AD - Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. FAU - Lee, Ju Hyun AU - Lee JH AD - Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea. FAU - Suh, Koung Jin AU - Suh KJ AD - Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea. FAU - Kim, Ji-Won AU - Kim JW AD - Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea. FAU - Kim, Jin Won AU - Kim JW AD - Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea. FAU - Kim, Se Hyun AU - Kim SH AD - Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea. FAU - Kim, Yu Jung AU - Kim YJ AD - Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea. FAU - Lee, Keun-Wook AU - Lee KW AD - Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea. FAU - Kim, Jwa Hoon AU - Kim JH AD - Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. AD - Division of Oncology, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea. FAU - Kim, Tae Won AU - Kim TW AD - Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. FAU - Hong, Yong Sang AU - Hong YS AD - Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. FAU - Kim, Sun Young AU - Kim SY AD - Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. FAU - Kim, Jeong Eun AU - Kim JE AD - Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. FAU - Kim, Sang-We AU - Kim SW AD - Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. FAU - Lee, Dae Ho AU - Lee DH AD - Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. FAU - Lee, Jae Cheol AU - Lee JC AD - Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. FAU - Choi, Chang-Min AU - Choi CM AD - Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. FAU - Yoon, Shinkyo AU - Yoon S AD - Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. FAU - Koh, Su-Jin AU - Koh SJ AD - Division of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea. FAU - Min, Young Joo AU - Min YJ AD - Division of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea. FAU - Ahn, Yongchel AU - Ahn Y AD - Department of Hematology and Oncology, Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung, Korea. FAU - Kim, Hwa Jung AU - Kim HJ AD - Department of Clinical Epidemiology and Biostatistics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. FAU - Baek, Jin Ho AU - Baek JH AD - Department of Oncology/Hematology, Kyungpook National University Chilgok Hospital, Kyungpook National University, Daegu, Korea. FAU - Park, Sook Ryun AU - Park SR AD - Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. FAU - Kim, Jee Hyun AU - Kim JH AD - Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea. LA - eng GR - SDR 10-012/HX/HSRD VA/United States GR - TPP 10-008/HX/HSRD VA/United States PT - Journal Article PT - Multicenter Study DEP - 20231107 PL - Korea (South) TA - Cancer Res Treat JT - Cancer research and treatment JID - 101155137 SB - IM MH - Humans MH - Male MH - Female MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/etiology MH - Retrospective Studies MH - *Lung Neoplasms/drug therapy MH - Nausea/drug therapy MH - Vomiting/drug therapy MH - *Neutropenia MH - Antineoplastic Combined Chemotherapy Protocols/adverse effects MH - Chemotherapy, Adjuvant/adverse effects PMC - PMC11016653 OTO - NOTNLM OT - Adjuvant chemotherapy OT - Adverse events OT - Sex characteristics COIS- Conflicts of Interest Conflict of interest relevant to this article was not reported. EDAT- 2023/11/07 06:45 MHDA- 2024/04/15 06:43 PMCR- 2024/04/01 CRDT- 2023/11/07 03:02 PHST- 2023/06/22 00:00 [received] PHST- 2023/11/06 00:00 [accepted] PHST- 2024/04/15 06:43 [medline] PHST- 2023/11/07 06:45 [pubmed] PHST- 2023/11/07 03:02 [entrez] PHST- 2024/04/01 00:00 [pmc-release] AID - crt.2023.784 [pii] AID - crt-2023-784 [pii] AID - 10.4143/crt.2023.784 [doi] PST - ppublish SO - Cancer Res Treat. 2024 Apr;56(2):404-413. doi: 10.4143/crt.2023.784. Epub 2023 Nov 7.